H3B-8800 NEW
| Price | $297 | $786 | $2890 |
| Package | 1mg | 5mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: H3B-8800 | CAS No.: 1825302-42-8 |
| Purity: 98.31% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | H3B-8800 |
| Description | H3B-8800 is a small-molecule inhibitor and an SF3B1-targeted inhibitor with oral bioactivity and cell permeability. This compound directly binds to the SF3b complex, exhibiting anticancer activity in transfusion-dependent myelodysplastic syndromes and SF3B1-mutant acute myeloid leukemia. |
| In vitro | Methods: SF3B1 wild-type and K700E mutant MEC1 chronic lymphocytic leukemia cells and primary CLL cells were incubated with 1–100 nM H3B-8800 for 48 h. Cell viability was detected by flow cytometry, and splicing changes were analyzed by RNA-seq. Results: H3B-8800 killed cells in a dose-dependent manner, showing stronger selectivity for SF3B1 mutant cells, induced widespread splicing alterations, and exhibited synergistic killing effects when combined with venetoclax. [1] Methods: SRSF2-P95H mutant and wild-type bone marrow cells and leukemia cells were treated with gradient concentrations of H3B-8800, and in vitro activity was assessed through cell viability detection and RNA splicing analysis. Results:H3B-8800 selectively killed SRSF2 mutant cells, induced intron retention in GC-rich regions, significantly inhibited aberrant splicing and reduced leukemia cell burden, with weaker effects on wild-type cells. [2] |
| In vivo | Methods: NSG immunodeficient mice were used to establish a MEC1 cell CLL xenograft model, with SF3B1 wild-type and K700E mutant cells inoculated via tail vein injection. H3B-8800 was administered by daily oral gavage at 6 mg/kg in a solvent mixture containing methylcellulose and ethanol for 10 consecutive days. Results: H3B-8800 significantly reduced bone marrow leukemic infiltration in the SF3B1 K700E group, alleviated hepatosplenomegaly, and delayed tumor infiltration. [3] |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 122.5 mg/mL (220.44 mM), Sonication is recommended. |
| Keywords | SF3B1 | H3B-8800 | H3B8800 | H3B 8800 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1130.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-09-17 | |
|
VIP1Y
|
ACROBiosystems
|
2026-07-02 | ||
| $2530.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-07-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY